Valion Bio Announces Positive Safety Results From U.S. Government-Funded Entolimod Study, Paving Way For Therapeutic Efficacy Evaluation
Valion Bio announced final results from a government-funded safety study of its lead candidate Entolimod, a TLR5 agonist being developed as a medical countermeasure for acute radiation syndrome. The AFRRI-conducted study in 20 mice showed no statistically significant differences versus saline control in body weight, blood counts, or serum chemistry, with no treatment-related toxicity observed over 14 days.
Key figures
- Drug Name
- Entolimod
- Phase Of Trial
- Preclinical safety study (GLP-style mouse model)
- Dose
- 0.72 mg/kg single subcutaneous injection
- Study size
- 20 male C57BL/6 mice
- Observation period
- 14 days
- Body weight p value
- p = 0.1424 (no significant difference vs control)
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.